Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inhibrx, Inc. (INBX : NSDQ)

• Company Description    Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Number of Employees: 112

• Price / Volume Information    Yesterday's Closing Price: $13.73 Daily Weekly Monthly 20 Day Moving Average: 454,769 shares Shares Outstanding: 39.04 (millions) Market Capitalization: $535.98 (millions) Beta: 3.06 52 Week High: $47.90 52 Week Low: $12.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.56% -15.15% 12 Week -36.32% -30.90% Year To Date -68.56% -62.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11025 NORTH TORREY PINES ROAD SUITE 200 - LA JOLLA,CA 92037 USA ph: 858-795-4220 fax: - amy@juniper-point.com http://www.inhibrx.com

• General Corporate Information    Officers Mark P. Lappe - Chief Executive Officer and Chairman Kelly D. Deck - Chief Financial Officer Jon Faiz Kayyem - Director Douglas G. Forsyth - Director Kimberly Manhard - Director Peer Information Inhibrx, Inc. (CORR.) Inhibrx, Inc. (RSPI) Inhibrx, Inc. (CGXP) Inhibrx, Inc. (BGEN) Inhibrx, Inc. (GTBP) Inhibrx, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45720L107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 39.04 Most Recent Split Date: (:1) Beta: 3.06 Market Capitalization: $535.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 19.60 Price/Cash Flow: - Price / Sales: 73.71 EPS Growth vs. Year Ago Period: -56.86% vs. Previous Quarter: -45.45% Sales Growth vs. Year Ago Period: 4.50% vs. Previous Quarter: -67.47% ROE 03/31/22 - -246.26 12/31/21 - -176.32 09/30/21 - -150.02 ROA 03/31/22 - -64.34 12/31/21 - -59.90 09/30/21 - -58.02 Current Ratio 03/31/22 - 7.48 12/31/21 - 6.20 09/30/21 - 4.73 Quick Ratio 03/31/22 - 7.48 12/31/21 - 6.20 09/30/21 - 4.73 Operating Margin 03/31/22 - -1,289.14 12/31/21 - -1,130.80 09/30/21 - -1,093.94 Net Margin 03/31/22 - -1,289.14 12/31/21 - -1,130.80 09/30/21 - -1,093.94 Pre-Tax Margin 03/31/22 - -1,289.14 12/31/21 - -1,130.77 09/30/21 - -1,093.88 Book Value 03/31/22 - 0.70 12/31/21 - 1.38 09/30/21 - 0.74 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 4.16 12/31/21 - 1.44 09/30/21 - 2.68 Debt-to-Capital 03/31/22 - 80.61 12/31/21 - 59.04 09/30/21 - 72.82

Powered by Zacks Investment Research ©